Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study (vol 11, pg 573, 2024)

被引：0

作者：

Fautrel, Bruno ^{[1
]}

Bouhnik, Yoram ^{[2
]}

Salliot, Carine ^{[3
]}

Carbonnel, Franck ^{[4
]}

Fumery, Mathurin ^{[5
]}

Bernardeau, Christophe ^{[6
]}

Maugars, Yves ^{[7
,8
,9
]}

Flamant, Mathurin ^{[10
]}

Coury, Fabienne ^{[11
,12
]}

Braithwaite, Ben ^{[13
]}

Hateb, Salima ^{[14
]}

Addison, Janet ^{[15
]}

PERFUSE Investigators

机构：

[1] Sorbonne Univ, Hop Pitie Salpetriere, AP HP, INSERM,UMRS 1136, Paris, France

[2] Grp Hosp Prive Ambroise Pare Hartmann, Paris IBD Ctr, Neuilly Sur Seine, France

[3] Ctr Hosp Univ dOrleans, Rheumatol Dept, Orleans, France

[4] Hop Bicetre, AP HP, Le Kremlin Bicetre, France

[5] CHU Amiens, Dept Gastroenterol, Amiens, France

[6] Clin Francois Chenieux, Limoges, France

[7] Univ Nantes, Inserm, UMR 1229, ONIRIS,RMeS Regenerat Med & Skeleton, Nantes, France

[8] Univ Nantes, Odontol Dept, Nantes, France

[9] CHU Nantes, Dept Rheumatol, Nantes, France

[10] Clin Jules Verne, Dept Gastroenterol, Nantes, France

[11] Univ Lyon, Lyon Sud Hosp, Hosp Civils Lyon, Rheumatol Dept, Lyon, France

[12] Lyon Immunopathol Federat, INSERM UMR 1033, Lyon, France

[13] Sanoia eHlth Serv, 188 Av 2nd Div Blindee, F-13420 Gardanne, France

[14] Biogen France SAS, Gastroenterol & Rhumatol, Biosimilars, Courbevoie, France

[15] Clin Res Biosimilars, Biogen IDEC, Maidenhead, England

来源：

DRUGS-REAL WORLD OUTCOMES | 2025年 / 12卷 / 01期

关键词：

D O I：

10.1007/s40801-024-00477-4

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：163 / 164

页数：2

共 5 条

[1] Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study
Fautrel, Bruno
Bouhnik, Yoram
Salliot, Carine
Carbonnel, Franck
Fumery, Mathurin
Bernardeau, Christophe
Maugars, Yves
Flamant, Mathurin
Coury, Fabienne
Braithwaite, Ben
Hateb, Salima
Addison, Janet
DRUGS-REAL WORLD OUTCOMES, 2024, 11 (04) : 573 - 591
[2] The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune-Mediated Inflammatory Disease
Mueller-Ladner, Ulf
Dignass, Axel
Gaffney, Karl
Jadon, Deepak
Matucci-Cerinic, Marco
Lobaton, Triana
Carron, Philippe
Gisbert, Javier P.
Pande, Ira
Utzinger, Maximilian
Addison, Janet
BIODRUGS, 2023, 37 (06) : 873 - 889
[3] The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune‐Mediated Inflammatory Disease
Ulf Müller-Ladner
Axel Dignass
Karl Gaffney
Deepak Jadon
Marco Matucci-Cerinic
Triana Lobaton
Philippe Carron
Javier P. Gisbert
Ira Pande
Maximilian Utzinger
Janet Addison
BioDrugs, 2023, 37 : 873 - 889
[4] Comparison of biologic use in pivotal clinical trials versus real-world setting with immune-mediated inflammatory diseases: An Italian population-based study from the VALORE project
Ingrasciotta, Ylenia
Fiore, Elena Sofia
L'Abbate, Luca
Carollo, Massimo
Ientile, Valentina
Spini, Andrea
Cavazzana, Anna
Biasi, Valeria
Rossi, Paola
Ejlli, Lucian
Belleudi, Valeria
Lopes, Sara
Sapigni, Ester
Puccini, Aurora
Ancona, Domenica
Stella, Paolo
Addario, Sebastiano Pollina
Allotta, Alessandra
Leoni, Olivia
Zanforlini, Martina
Tuccori, Marco
Gini, Rosa
Trifiro, Gianluca
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 295 - 295
[5] Patient-reported Outcomes and Safety Measures in Patients with Rheumatic Diseases Who Switched from Reference or Other Biosimilar Etanercept to Biosimilar Etanercept GP2015 and in Biologic-naive Patients Starting a Treatment with GP2015: 12-month Interim Analysis from a Real-world Study
Askari, Ayman
Schmalzing, Marc
Jeka, Slawomir
Santos, Javier De Toro
Collantes-Estevez, Eduardo
Furlan, Fabricio
Hachaichi, Sohaib
Kellner, Herbert
ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1509 - 1511

← 1 →